IRLAB Therapeutics AB (OSTO:IRLAB A) 3-Month Share Buyback Ratio : 0.00% (As of Mar. 2025 )

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. IRLAB Therapeutics AB's current 3-Month Share Buyback Ratio was 0.00%.

Competitive Comparison of IRLAB Therapeutics AB's 3-Month Share Buyback Ratio

For the Biotechnology subindustry, IRLAB Therapeutics AB's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRLAB Therapeutics AB's 3-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's 3-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

IRLAB Therapeutics AB 3-Month Share Buyback Ratio Calculation

IRLAB Therapeutics AB's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2025 is calculated as

3-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2024 )	-	Shares Outstanding (EOP) (Mar. 2025 ))	/	Shares Outstanding (EOP) (Dec. 2024 )
	=	(54.940	-	54.940)	/	54.940
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRLAB Therapeutics AB (OSTO:IRLAB A) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

IRLAB Therapeutics AB 3-Month Share Buyback Ratio Related Terms

IRLAB Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » 3-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines